Long-term incidence of implantable cardioverter-defibrillator therapy in patients with hypertrophic cardiomyopathy: analysis of appropriate and inappropriate interventions.

IF 5.1 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Heart Pub Date : 2025-01-19 DOI:10.1136/heartjnl-2024-325020
Emma Basse Christensen, Christoffer Rasmus Vissing, Elvira Silajdzija, Helen Lamiokor Mills, Jens Jakob Thune, Charlotte Larroudé, Helle Skovmand Bosselmann, Berit Thornvig Philbert, Anna Axelsson Raja, Alex Hørby Christensen, Henning Bundgaard
{"title":"Long-term incidence of implantable cardioverter-defibrillator therapy in patients with hypertrophic cardiomyopathy: analysis of appropriate and inappropriate interventions.","authors":"Emma Basse Christensen, Christoffer Rasmus Vissing, Elvira Silajdzija, Helen Lamiokor Mills, Jens Jakob Thune, Charlotte Larroudé, Helle Skovmand Bosselmann, Berit Thornvig Philbert, Anna Axelsson Raja, Alex Hørby Christensen, Henning Bundgaard","doi":"10.1136/heartjnl-2024-325020","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatment with implantable cardioverter-defibrillators (ICDs) effectively prevents sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). Identifying patients most likely to benefit from a primary prevention ICD remains challenging. We aimed to investigate the long-term incidence of ICD therapy in patients with HCM according to SCD-risk at baseline.</p><p><strong>Methods: </strong>The study retrospectively included all patients with HCM treated with an ICD for primary or secondary prevention between 1995 and 2022 in Eastern Denmark. Medical records for each patient were evaluated. Patients were stratified into risk groups according to the European Society of Cardiology HCM Risk-SCD score.</p><p><strong>Results: </strong>We included 208 patients (66% male) with HCM and an ICD for primary (78%) or secondary prevention (22%). During a median 10-year follow-up, 66 patients (32%) received appropriate ICD therapy (antitachycardia pacing and/or shock), while 20 (10%) received inappropriate therapy. Patients with an ICD implanted for secondary prevention were almost twice as likely to receive appropriate therapy compared with patients with an ICD implanted for primary prevention (47% vs 28%, p=0.02). The 5-year cumulative incidences of appropriate shock therapy were 17% in patients with a high HCM Risk-SCD score, 16% in patients with an intermediate-risk score and 6% in patients with a low-risk score. A high-risk score was associated with higher cumulative incidence of appropriate shock therapy (p=0.012).</p><p><strong>Conclusion: </strong>One-third of patients with HCM treated with an ICD experienced appropriate ICD therapy. The HCM-Risk SCD score adequately distinguished between low-risk and high-risk patients among those who underwent ICD implantation. Further improvements of risk-tools are needed to identify a larger proportion of the two-thirds of patients who did not benefit from ICD implantation after 10 years of observation.</p>","PeriodicalId":12835,"journal":{"name":"Heart","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/heartjnl-2024-325020","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Treatment with implantable cardioverter-defibrillators (ICDs) effectively prevents sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). Identifying patients most likely to benefit from a primary prevention ICD remains challenging. We aimed to investigate the long-term incidence of ICD therapy in patients with HCM according to SCD-risk at baseline.

Methods: The study retrospectively included all patients with HCM treated with an ICD for primary or secondary prevention between 1995 and 2022 in Eastern Denmark. Medical records for each patient were evaluated. Patients were stratified into risk groups according to the European Society of Cardiology HCM Risk-SCD score.

Results: We included 208 patients (66% male) with HCM and an ICD for primary (78%) or secondary prevention (22%). During a median 10-year follow-up, 66 patients (32%) received appropriate ICD therapy (antitachycardia pacing and/or shock), while 20 (10%) received inappropriate therapy. Patients with an ICD implanted for secondary prevention were almost twice as likely to receive appropriate therapy compared with patients with an ICD implanted for primary prevention (47% vs 28%, p=0.02). The 5-year cumulative incidences of appropriate shock therapy were 17% in patients with a high HCM Risk-SCD score, 16% in patients with an intermediate-risk score and 6% in patients with a low-risk score. A high-risk score was associated with higher cumulative incidence of appropriate shock therapy (p=0.012).

Conclusion: One-third of patients with HCM treated with an ICD experienced appropriate ICD therapy. The HCM-Risk SCD score adequately distinguished between low-risk and high-risk patients among those who underwent ICD implantation. Further improvements of risk-tools are needed to identify a larger proportion of the two-thirds of patients who did not benefit from ICD implantation after 10 years of observation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肥厚性心肌病患者植入式心律转复除颤器治疗的长期发病率:适当和不适当干预措施的分析。
背景:植入式心律转复除颤器(ICDs)治疗可有效预防肥厚性心肌病(HCM)患者的心源性猝死(SCD)。确定最有可能从一级预防ICD中受益的患者仍然具有挑战性。我们的目的是根据基线scd风险调查HCM患者ICD治疗的长期发生率。方法:回顾性研究纳入1995年至2022年丹麦东部所有接受ICD一级或二级预防治疗的HCM患者。对每位患者的医疗记录进行了评估。根据欧洲心脏病学会HCM风险- scd评分将患者分为危险组。结果:我们纳入了208例HCM患者(66%为男性),ICD用于一级预防(78%)或二级预防(22%)。在中位10年随访期间,66例(32%)患者接受了适当的ICD治疗(抗心动过速起搏和/或休克),而20例(10%)患者接受了不适当的治疗。与植入式ICD用于一级预防的患者相比,植入式ICD用于二级预防的患者接受适当治疗的可能性几乎是植入式ICD的两倍(47% vs 28%, p=0.02)。在HCM - scd评分高的患者中,适当休克治疗的5年累积发生率为17%,中危评分患者为16%,低危评分患者为6%。高风险评分与较高的休克治疗累积发生率相关(p=0.012)。结论:三分之一接受ICD治疗的HCM患者接受了适当的ICD治疗。HCM-Risk SCD评分可以充分区分ICD植入患者中的低风险和高风险患者。需要进一步改进风险工具,以确定在10年观察后没有从ICD植入中获益的三分之二患者中的更大比例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Heart
Heart 医学-心血管系统
CiteScore
10.30
自引率
5.30%
发文量
320
审稿时长
3-6 weeks
期刊介绍: Heart is an international peer reviewed journal that keeps cardiologists up to date with important research advances in cardiovascular disease. New scientific developments are highlighted in editorials and put in context with concise review articles. There is one free Editor’s Choice article in each issue, with open access options available to authors for all articles. Education in Heart articles provide a comprehensive, continuously updated, cardiology curriculum.
期刊最新文献
Prognostic implications of iron deficiency in patients with atrial fibrillation, with and without chronic heart failure. Effects of routine invasive management on reinfarction risk in older adults with frailty and non-ST-segment elevation myocardial infarction: a subanalysis of a randomised clinical trial. Albuminuria and cardiovascular outcomes in early-stage chronic kidney disease. Shaping the future of cardiovascular medicine: advancing morphological atlases. The ICAM1 p.K56M variant and risk of heart failure in chronic kidney disease: the Chronic Renal Insufficiency Cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1